Cassava Sciences Inc (SAVA)
22.05
-0.01
(-0.05%)
USD |
NASDAQ |
May 03, 16:00
22.17
+0.12
(+0.54%)
After-Hours: 20:00
Cassava Sciences Enterprise Value: 831.98M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 831.98M |
May 02, 2024 | 832.41M |
May 01, 2024 | 835.87M |
April 30, 2024 | 836.30M |
April 29, 2024 | 842.79M |
April 26, 2024 | 844.52M |
April 25, 2024 | 818.15M |
April 24, 2024 | 775.35M |
April 23, 2024 | 767.14M |
April 22, 2024 | 764.98M |
April 19, 2024 | 727.81M |
April 18, 2024 | 794.81M |
April 17, 2024 | 798.26M |
April 16, 2024 | 787.89M |
April 15, 2024 | 743.80M |
April 12, 2024 | 862.24M |
April 11, 2024 | 1.007B |
April 10, 2024 | 938.31M |
April 09, 2024 | 976.78M |
April 08, 2024 | 897.68M |
April 05, 2024 | 799.99M |
April 04, 2024 | 764.12M |
April 03, 2024 | 768.44M |
April 02, 2024 | 730.83M |
April 01, 2024 | 755.90M |
Date | Value |
---|---|
March 28, 2024 | 755.90M |
March 27, 2024 | 761.52M |
March 26, 2024 | 730.83M |
March 25, 2024 | 730.40M |
March 22, 2024 | 735.16M |
March 21, 2024 | 794.37M |
March 20, 2024 | 828.52M |
March 19, 2024 | 829.39M |
March 18, 2024 | 798.70M |
March 15, 2024 | 799.13M |
March 14, 2024 | 773.19M |
March 13, 2024 | 771.46M |
March 12, 2024 | 778.38M |
March 11, 2024 | 675.94M |
March 08, 2024 | 690.63M |
March 07, 2024 | 710.95M |
March 06, 2024 | 736.45M |
March 05, 2024 | 804.32M |
March 04, 2024 | 851.86M |
March 01, 2024 | 873.04M |
February 29, 2024 | 872.18M |
February 28, 2024 | 870.02M |
February 27, 2024 | 873.04M |
February 26, 2024 | 826.36M |
February 23, 2024 | 805.12M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.561M
Minimum
May 20 2019
5.135B
Maximum
Jul 28 2021
875.98M
Average
781.26M
Median
Nov 16 2023
Enterprise Value Benchmarks
Amylyx Pharmaceuticals Inc | -233.76M |
Clearside Biomedical Inc | 68.96M |
Lantern Pharma Inc | 24.76M |
NovaBay Pharmaceuticals Inc | 2.813M |
Palatin Technologies Inc | 24.56M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -20.92M |
Total Expenses (Quarterly) | 22.79M |
EPS Diluted (Quarterly) | -0.50 |
Earnings Yield | -10.52% |
Operating Earnings Yield | 3.39% |
Normalized Earnings Yield | 21.59 |